Biocon Biologics settled with the maker of Eylea (aflibercept), announcing a launch date for its biosimilar competitor in Canada; Sandoz has officially acquired Cimerli, a ranibizumab biosimilar; AARP Medicare Rx from United Healthcare has added Cyltezo (adalimumab-adbm) and removed the originator (Humira) from its formulary.
Biocon Biologics reached a settlement with the maker of Eylea (aflibercept), announcing a launch date for its biosimilar competitor in Canada; Sandoz has officially acquired Cimerli, a ranibizumab biosimilar; AARP Medicare Rx from United Healthcare has added Cyltezo (adalimumab-adbm) and removed the originator (Humira) from its formulary.
Aflibercept Settlement in Canada
Biocon Biologics settled with Bayer and Regeneron Pharmaceuticals regarding its aflibercept biosimilar candidate (Yesafili), allowing it to launch in Canada no sooner than July 1, 2025, according to a report from Business Standard.
Yesafili received tentative approval from Health Canada in March 2023. Yesafili is used to treat various eye diseases, including neovascular age-related macular degeneration, central retinal vein occlusion, branch retinal vein occlusion, diabetic macular edema, and myopic choroidal neovascularization.
This settlement followed patent infringement proceedings in Canada. Biocon Biologics has been expanding its biosimilar portfolio globally, with Yesafili already receiving marketing authorization in the United Kingdom and the European Union in November and September 2023, respectively.
Sandoz Acquires Ranibizumab Biosimilar
Sandoz announced that it has completed the acquisition of Cimerli (ranibizumab-eqrn), a biosimilar referencing Lucentis (ranibizumab), from Coherus Biosciences.
The biosimilar was approved in August 2022 and launched on the US market in October 2022. Cimerli was also one of the first biosimilars to receive an interchangeability designation. Ranibizumab products are vascular endothelial growth factor inhibitors used to treat neovascular age-related macular degeneration, diabetic retinopathy, and macular edema.
The acquisition included a biologics license application, product inventory, ophthalmology sales and field reimbursement talent, and access to proprietary commercial software. Sandoz disclosed that it paid $170 million in upfront payments.
“Today we further expand the Sandoz biosimilar portfolio, while advancing our mission in the U.S. of pioneering patient access to more affordable and much-needed medicines,” Keren Haruvi, president of Sandoz North America, said in the release. “With the addition of Cimerli to our existing ophthalmology franchise, we can now offer even more treatment options for U.S. patients with vision impairment and loss.”
Trend of Payers Choosing Adalimumab Biosimilars Over Humira Continues
AARP Medicare Rx from United Healthcare has chosen to add Cyltezo, an interchangeable adalimumab biosimilar, to its formulary in place of Humira, the originator. Cyltezo is also the only adalimumab biosimilar on the list.
Adalimumab products are used to treat a number of inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, Crohn disease, hidradenitis suppurativa, ankylosing spondylitis, uveitis, and juvenile idiopathic arthritis.
The news comes after CVS Health announced that it would remove Humira from some of its reimbursement lists in favor of Cyltezo and Abrilada (adalimumab-afzb). Additionally, the Mark Cuban Cost Plus Drug Company, an online pharmacy dedicated to improving access to lower-cost generics, chose Coherus Biosciences’ Yusimry (adalimumab-aqvh) as the only adalimumab biosimilar and first biologic to offer to its customers.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Eye on Pharma: EU Biosimilar Approval, Launches and Product Returns, Denosumab Switching Data
July 10th 2024The European Union approves a tocilizumab biosimilar and the US sees another launch, Genentech’s ophthalmology biobetter returns to the market, and Samsung Bioepis shares data on switching to its denosumab biosimilar.